MX2016003016A - Pruebas diagnosticas moleculares para cancer pulmonar. - Google Patents
Pruebas diagnosticas moleculares para cancer pulmonar.Info
- Publication number
- MX2016003016A MX2016003016A MX2016003016A MX2016003016A MX2016003016A MX 2016003016 A MX2016003016 A MX 2016003016A MX 2016003016 A MX2016003016 A MX 2016003016A MX 2016003016 A MX2016003016 A MX 2016003016A MX 2016003016 A MX2016003016 A MX 2016003016A
- Authority
- MX
- Mexico
- Prior art keywords
- lung cancer
- test
- diagnostic test
- molecular diagnostic
- responsiveness
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 2
- 238000002405 diagnostic procedure Methods 0.000 title abstract 2
- 201000005202 lung cancer Diseases 0.000 title abstract 2
- 208000020816 lung neoplasm Diseases 0.000 title abstract 2
- 230000004043 responsiveness Effects 0.000 abstract 2
- 238000011285 therapeutic regimen Methods 0.000 abstract 2
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 230000005971 DNA damage repair Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan métodos y composiciones para la identificación de una prueba diagnóstica molecular para cáncer de pulmón. La prueba define un subtipo molecular deficiente para la reparación del daño del DNA, novedoso y hace posible la clasificación de un paciente dentro de este subtipo. La presente invención puede utilizarse para determinar si los pacientes con NSCLC son sensibles o no sensibles desde el punto de vista clínico a un régimen terapéutico antes de la administración de cualquier quimioterapia. Esta prueba puede utilizarse con diferentes fármacos que afecten directa o indirectamente el daño o la reparación del DNA, como puede ser los múltiples fármacos quimioterapéuticos, citotóxicos, normales que actualmente se utilizan. En particular, la presente invención se dirige al uso de ciertas combinaciones de marcadores predictivos, en donde la expresión de los marcadores predictivos se correlaciona con la sensibilidad o no sensibilidad a un régimen terapéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1316024.7A GB201316024D0 (en) | 2013-09-09 | 2013-09-09 | Molecular diagnostic test for lung cancer |
| PCT/GB2014/052728 WO2015033173A1 (en) | 2013-09-09 | 2014-09-09 | Molecular diagnostic test for lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016003016A true MX2016003016A (es) | 2016-06-24 |
Family
ID=49486938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003016A MX2016003016A (es) | 2013-09-09 | 2014-09-09 | Pruebas diagnosticas moleculares para cancer pulmonar. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160222459A1 (es) |
| EP (1) | EP3044328A1 (es) |
| JP (1) | JP2016536001A (es) |
| KR (1) | KR20160052729A (es) |
| CN (1) | CN105874079A (es) |
| AU (1) | AU2014316824A1 (es) |
| CA (1) | CA2923528A1 (es) |
| GB (1) | GB201316024D0 (es) |
| IL (1) | IL244472A0 (es) |
| MX (1) | MX2016003016A (es) |
| SG (1) | SG11201601722XA (es) |
| WO (1) | WO2015033173A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
| US20140136508A1 (en) | 2012-11-09 | 2014-05-15 | Palo Alto Research Center Incorporated | Computer-Implemented System And Method For Providing Website Navigation Recommendations |
| EP2972373B1 (en) | 2013-03-15 | 2019-10-09 | F.Hoffmann-La Roche Ag | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| WO2015181342A1 (en) | 2014-05-29 | 2015-12-03 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
| MX384364B (es) | 2014-07-11 | 2025-03-14 | Ventana Med Syst Inc | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. |
| EP3254110B1 (en) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| US10438130B2 (en) * | 2015-12-01 | 2019-10-08 | Palo Alto Research Center Incorporated | Computer-implemented system and method for relational time series learning |
| US11436656B2 (en) | 2016-03-18 | 2022-09-06 | Palo Alto Research Center Incorporated | System and method for a real-time egocentric collaborative filter on large datasets |
| CA3016340A1 (en) * | 2016-03-21 | 2017-09-28 | Nantomics, Llc | Ercc1 and other markers for stratification of non-small cell lung cancer patients |
| US11093834B2 (en) | 2016-07-06 | 2021-08-17 | Palo Alto Research Center Incorporated | Computer-implemented system and method for predicting activity outcome based on user attention |
| CN106755322A (zh) * | 2016-11-25 | 2017-05-31 | 苏州首度基因科技有限责任公司 | 一种预测肺癌转移的试剂盒及其使用方法 |
| KR101875462B1 (ko) * | 2016-12-29 | 2018-07-06 | 강원대학교산학협력단 | FosB 유전자 프로모터를 이용한 종양 환자의 항암제 내성 진단용 바이오마커 및 이를 이용한 항암제 내성 진단용 킷트 |
| JP2020512977A (ja) | 2017-03-31 | 2020-04-30 | シアトル ジェネティックス， インコーポレイテッド | Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ |
| CN107142298A (zh) * | 2017-06-15 | 2017-09-08 | 大连理工大学 | 一种细胞周期阻滞剂6bar在人肺癌细胞中的应用 |
| EP3645563A4 (en) | 2017-06-27 | 2021-03-17 | Neuracle Science Co., Ltd | ANTI-FAM19A5 ANTIBODIES AND USES THEREOF |
| US12072339B2 (en) * | 2017-10-02 | 2024-08-27 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment and diagnosis of mood disorders |
| JP7401442B2 (ja) * | 2018-01-31 | 2023-12-19 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| JP7455757B2 (ja) * | 2018-04-13 | 2024-03-26 | フリーノーム・ホールディングス・インコーポレイテッド | 生体試料の多検体アッセイのための機械学習実装 |
| CN109295208A (zh) * | 2018-10-26 | 2019-02-01 | 德阳市人民医院 | Pi15作为骨关节炎标志物的应用 |
| CN109880903B (zh) * | 2019-03-01 | 2021-12-14 | 南京医科大学 | 一种用于非小细胞肺癌辅助诊断的snp标志物及其应用 |
| CN110246544B (zh) * | 2019-05-17 | 2021-03-19 | 暨南大学 | 一种基于整合分析的生物标志物选择方法及系统 |
| CN114173880A (zh) * | 2019-05-17 | 2022-03-11 | 纪念斯隆凯特琳癌症中心 | 预测癌症对铁死亡诱导疗法的反应性的方法 |
| CN110456085A (zh) * | 2019-09-20 | 2019-11-15 | 四川大学华西医院 | Syt12自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN111381047A (zh) * | 2020-03-19 | 2020-07-07 | 四川大学华西第二医院 | Fbxo2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| JP7464977B2 (ja) * | 2020-06-10 | 2024-04-10 | 国立大学法人東京農工大学 | イヌ中皮腫細胞株 |
| CN112522409A (zh) * | 2020-12-29 | 2021-03-19 | 北京泱深生物信息技术有限公司 | 基因标志物组合在肺癌筛查和预后判断中的应用 |
| CN114540504B (zh) * | 2022-04-27 | 2022-07-08 | 广州万德基因医学科技有限公司 | 用于预测肺鳞癌患者免疫疗效的标志物组及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| JP2006211994A (ja) * | 2005-02-07 | 2006-08-17 | Seibutsu Yuki Kagaku Kenkyusho:Kk | 非小細胞肺癌に対する抗癌剤の抗癌特性決定方法 |
| US20070172844A1 (en) * | 2005-09-28 | 2007-07-26 | University Of South Florida | Individualized cancer treatments |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| ES2805347T3 (es) * | 2009-02-11 | 2021-02-11 | Caris Mpi Inc | Perfilado molecular de tumores |
| CN103237901B (zh) * | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| EA201390370A1 (ru) * | 2010-09-15 | 2013-07-30 | Олмак Дайэгностикс Лимитед | Молекулярно-диагностический тест для определения онкологического заболевания |
-
2013
- 2013-09-09 GB GBGB1316024.7A patent/GB201316024D0/en not_active Ceased
-
2014
- 2014-09-09 JP JP2016539639A patent/JP2016536001A/ja active Pending
- 2014-09-09 SG SG11201601722XA patent/SG11201601722XA/en unknown
- 2014-09-09 WO PCT/GB2014/052728 patent/WO2015033173A1/en not_active Ceased
- 2014-09-09 AU AU2014316824A patent/AU2014316824A1/en not_active Abandoned
- 2014-09-09 CA CA2923528A patent/CA2923528A1/en not_active Abandoned
- 2014-09-09 US US14/917,913 patent/US20160222459A1/en not_active Abandoned
- 2014-09-09 CN CN201480058968.8A patent/CN105874079A/zh active Pending
- 2014-09-09 MX MX2016003016A patent/MX2016003016A/es unknown
- 2014-09-09 EP EP14766776.0A patent/EP3044328A1/en not_active Withdrawn
- 2014-09-09 KR KR1020167009430A patent/KR20160052729A/ko not_active Withdrawn
-
2016
- 2016-03-07 IL IL244472A patent/IL244472A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016536001A (ja) | 2016-11-24 |
| GB201316024D0 (en) | 2013-10-23 |
| EP3044328A1 (en) | 2016-07-20 |
| CN105874079A (zh) | 2016-08-17 |
| AU2014316824A1 (en) | 2016-04-21 |
| WO2015033173A1 (en) | 2015-03-12 |
| US20160222459A1 (en) | 2016-08-04 |
| IL244472A0 (en) | 2016-04-21 |
| SG11201601722XA (en) | 2016-04-28 |
| CA2923528A1 (en) | 2015-03-12 |
| KR20160052729A (ko) | 2016-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016003016A (es) | Pruebas diagnosticas moleculares para cancer pulmonar. | |
| MY166040A (en) | Molecular diagnostic test for cancer | |
| MX2016003077A (es) | Prueba diagnostica molecular para cancer esofagico. | |
| SG195208A1 (en) | Molecular diagnostic test for cancer | |
| HK1214633A1 (zh) | 癌症的分子诊断测试 | |
| WO2015031808A3 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| NZ627443A (en) | Biological markers for identifying patients for treatment with vegf antagonists | |
| WO2014036387A3 (en) | Methods for diagnosis and treatment of cancer | |
| MX358517B (es) | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. | |
| MY180365A (en) | Markers of tumor cell response to anti-cancer therapy | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| BR112015012014A2 (pt) | proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb) | |
| EA201500334A1 (ru) | Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него | |
| MX381399B (es) | Formulaciones de coenzima q10 y métodos de uso. | |
| AR100353A1 (es) | Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3 | |
| HUE045724T2 (hu) | GRPR antagonisták GRPR-pozitív rák kimutatására, diagnózisára és kezelésére | |
| MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
| MX2016014414A (es) | Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. | |
| BR112018004207A2 (pt) | biomarcadores e métodos de tratamento de câncer | |
| BR112016016932A2 (pt) | Tratamento de neoplasia | |
| WO2013081645A3 (en) | Erbb3 mutations in cancer | |
| BR112015020054A2 (pt) | Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa | |
| Suckling | Correlated covariates in ANCOVA cannot adjust for pre-existing differences between groups. | |
| HK1186771A (en) | Molecular diagnostic test for cancer | |
| EP2836217A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS |